Cargando…
Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance
AIMS: Duchenne muscular dystrophy (DMD) is a severe and still incurable disease, with heart failure as a leading cause of death. The identification of a disease-modifying therapy may require early-initiated and long-term administration, but such type of therapeutic trial is not evident in humans. We...
Autores principales: | Buyse, Gunnar M., Van der Mieren, Gerry, Erb, Michael, D'hooge, Jan, Herijgers, Paul, Verbeken, Erik, Jara, Alejandro, Van Den Bergh, An, Mertens, Luc, Courdier-Fruh, Isabelle, Barzaghi, Patrizia, Meier, Thomas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639086/ https://www.ncbi.nlm.nih.gov/pubmed/18784063 http://dx.doi.org/10.1093/eurheartj/ehn406 |
Ejemplares similares
-
NQO1-Dependent Redox Cycling of Idebenone: Effects on Cellular Redox Potential and Energy Levels
por: Haefeli, Roman H., et al.
Publicado: (2011) -
A Morpholino Oligomer Therapy Regime That Restores Mitochondrial Function and Prevents mdx Cardiomyopathy
por: Viola, Helena M., et al.
Publicado: (2018) -
Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmd(mdx) rat model
por: Caudal, Dorian, et al.
Publicado: (2020) -
Sildenafil ameliorates cardiomyopathy in dystrophin-null (mdx) mice
por: Parchen, Candace M, et al.
Publicado: (2009) -
Increased Neointimal Thickening in Dystrophin-Deficient mdx Mice
por: Rauch, Uwe, et al.
Publicado: (2012)